Ruxolitinib Topical Cream

DRUG3 trials

Sponsors

University of Zurich, The Cleveland Clinic

Conditions

DermatomyositisExanthemaImmune-related Vitiligo-like-DepigmentationLichenoid Skin Rashes Under Anti-PD1 Tumor Therapy

Phase 2

Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities

Active, not recruitingNCT06399029

University of ZurichExanthema, Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy

Start: 2024-10-10End: 2026-05-01Updated: 2026-04-30

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

RecruitingNCT06857240

The Cleveland ClinicDermatomyositis

Start: 2025-06-01End: 2027-12-31Target: 15Updated: 2025-10-08

Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation

Active, not recruitingNCT07725432

University of ZurichImmune-related Vitiligo-like-Depigmentation

Start: 2024-07-25End: 2026-08-31Target: 34Updated: 2026-07-24